Fortress Biotech Reports Sharply Reduced 2025 Net Loss and Major Asset Monetization, Including $205M PRV Sale
FBIO has more than doubled off its 52-week low of $1.325.
Summary
Fortress Biotech reported a substantial reduction in its 2025 net loss and highlighted significant asset monetization events, including a $205 million PRV sale and multiple subsidiary acquisitions, which have strengthened its financial position.
Key Events · Financing and Capital Events · FBIO
-
Significant Reduction in Net Loss
Consolidated net loss attributable to common stockholders for the full year ended December 31, 2025, was $(1.9) million, a substantial improvement from $(55.9) million in 2024.
-
$205 Million PRV Sale by Subsidiary
Fortress's majority-owned subsidiary, Cyprium Therapeutics, closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million in March 2026, following the FDA approval of ZYCUBO®.
-
Fortress to Receive Substantial Proceeds from PRV Sale
Fortress expects to receive an aggregate of at least $100 million from Cyprium through potential future dividends and intercompany agreements related to the PRV sale.
-
Oaktree Loan Prepayment
Fortress made aggregate prepayments on its loan with Oaktree, reducing the outstanding principal balance to $15.0 million, partially funded by the PRV sale proceeds.
Analysis · FBIO · Life Sciences
Fortress Biotech's full-year 2025 financial results show a dramatic improvement, with the net loss attributable to common stockholders shrinking from $(55.9) million in 2024 to just $(1.9) million. This significant financial turnaround is bolstered by successful asset monetization strategies. The sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its subsidiary Cyprium Therapeutics for $205 million, previously disclosed on March 30, 2026, is a major cash infusion, with Fortress expecting to receive at least $100 million. This capital has already enabled a substantial prepayment on the Oaktree loan, reducing the outstanding balance to $15.0 million, significantly strengthening the balance sheet. Additionally, the acquisitions of Checkpoint Therapeutics and Avenue Therapeutics' subsidiary Baergic, along with the Crystalys Therapeutics financing, establish long-term royalty streams and upfront payments, validating Fortress's strategy of building diversified revenue streams and creating shareholder value.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBIO was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.6M. The 52-week trading range was $1.33 to $4.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.